These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 6992932)

  • 1. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.
    Reeve J; Meunier PJ; Parsons JA; Bernat M; Bijvoet OL; Courpron P; Edouard C; Klenerman L; Neer RM; Renier JC; Slovik D; Vismans FJ; Potts JT
    Br Med J; 1980 Jun; 280(6228):1340-4. PubMed ID: 6992932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of parathyroid hormone as a therapy for osteoporosis.
    Rubin MR; Bilezikian JP
    Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
    Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
    J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds.
    Podbesek R; Edouard C; Meunier PJ; Parsons JA; Reeve J; Stevenson RW; Zanelli JM
    Endocrinology; 1983 Mar; 112(3):1000-6. PubMed ID: 6822201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis.
    Reeve J; Hesp R; Williams D; Hulme P; Klenerman L; Zanelli JM; Darby AJ; Tregear GW; Parsons JA
    Lancet; 1976 May; 1(7968):1035-8. PubMed ID: 57447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis.
    Reeve J; Arlot M; Price TR; Edouard C; Hesp R; Hulme P; Ashby JP; Zanelli JM; Green JR; Tellez M
    Eur J Clin Invest; 1987 Oct; 17(5):421-8. PubMed ID: 3121346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
    Kurland ES; Cosman F; McMahon DJ; Rosen CJ; Lindsay R; Bilezikian JP
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3069-76. PubMed ID: 10999788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis.
    Miyakoshi N
    Curr Pharm Des; 2004; 10(21):2615-27. PubMed ID: 15320749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.
    Plotkin H; Gundberg C; Mitnick M; Stewart AF
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2786-91. PubMed ID: 9709948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.
    Slovik DM; Neer RM; Potts JT
    J Clin Invest; 1981 Nov; 68(5):1261-71. PubMed ID: 7298851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.
    de Bakker CM; Altman AR; Tseng WJ; Tribble MB; Li C; Chandra A; Qin L; Liu XS
    Bone; 2015 Apr; 73():198-207. PubMed ID: 25554598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone: an anabolic treatment for osteoporosis.
    Morley P; Whitfield JF; Willick GE
    Curr Pharm Des; 2001 May; 7(8):671-87. PubMed ID: 11375775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-47 kinetic measurements of bone turnover compared to bone histomorphometry in osteoporosis: the influence of human parathyroid fragment (hPTH 1-34) therapy.
    Reeve J; Arlot M; Bernat M; Charhon S; Edouard C; Slovik D; Vismans FJ; Meunier PJ
    Metab Bone Dis Relat Res; 1981; 3(1):23-30. PubMed ID: 7266363
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
    Reeve J; Davies UM; Hesp R; McNally E; Katz D
    BMJ; 1990 Aug; 301(6747):314-8. PubMed ID: 2393738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Parathyroid hormone in osteoporosis].
    Cormier C
    Presse Med; 2006 Mar; 35(3 Pt 2):495-501. PubMed ID: 16550149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
    Adis International Ltd
    Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
    Miki T; Nakatsuka K; Naka H; Masaki H; Imanishi Y; Ito M; Inaba M; Morii H; Nishizawa Y
    J Bone Miner Metab; 2004; 22(6):569-76. PubMed ID: 15490267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.